CCGIX
Global Growth Fund
inception date
4/15/2016
cusip
057071581
total fund aum (millions)
$429.50
As of 10/31/2026
gross/net expense ratio %
0.84/0.80*
morningstar category
Global Large-Stock Growth
What is the Baird Chautauqua Global Growth Fund
The Baird Chautauqua Global Growth Fund is an actively managed, concentrated global equity strategy that invests in high-quality, medium to large capitalization U.S. and non-U.S. companies. The portfolio focuses on businesses the team believes can benefit from long-term global and macroeconomic trends while maintaining sustainable competitive advantages. Through a disciplined research process, the fund seeks long-term capital appreciation.
Performance
ALL DATA AS OF 10/31/2026
| 1 Month | 3 Month | YTD | 1 Year | 3 Years | 5 Years | 10 Years | Since Inception | |
|---|---|---|---|---|---|---|---|---|
| Global Growth Fund | 1.19 | 1.95 | 6.64 | 8.38 | 20.53 | 6.62 | 12.78 | 12.28 |
| MSCI AC World Index | -1.64 | -0.14 | 11.18 | 12.33 | 22.30 | 10.10 | 12.39 | 12.03 |
Morningstar Ratings
MORNINGSTAR RATINGS BASED ON RISK ADJUSTED RETURNS AS OF 10/31/2026
| Category | Overall | 3 Year | 5 Year | 10 Year | |
|---|---|---|---|---|---|
| Global Growth Fund | Global Large-Stock Growth |
(286 funds)
|
(286 funds)
|
(274 funds)
|
(201 funds)
|
Distributions
Time Period
| Type | Record Date | Reinvest Date | Payable Date | Amount per Share ($) | Reinvest Price ($) |
|---|---|---|---|---|---|
| Income | 12/26/2025 | 12/29/2025 | 12/30/2025 | 0.09175534 | 28.30 |
| Short Term Capital Gain | 12/12/2025 | 12/15/2025 | 12/16/2025 | 0.11209000 | 27.71 |
| Long Term Capital Gain | 12/12/2025 | 12/15/2025 | 12/16/2025 | 0.69980000 | 27.71 |
This fund pays annual distributions in December
Portfolio Characteristics
ALL DATA AS OF 9/30/2026
| Security | % of Fund |
|---|---|
| Taiwan Semiconductor | 5.76% |
| ASML Holding N.V. | 4.75% |
| Incyte Corporation | 4.03% |
| Recruit Holdings Co., Ltd. | 3.90% |
| Alphabet Inc. | 3.90% |
| Mastercard Inc. | 3.89% |
| Amazon.com, Inc. | 3.72% |
| Charles Schwab Corporation | 3.69% |
| Genmab A/S | 3.64% |
| BeOne Medicines | 3.58% |